Cerebrospinal fluid neopterin: An informative biomarker of central nervous system immune activation in HIV-1 infection

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Hagberg, Lars ^a   Cinque, Paola ^b   Gisslen, Magnus ^a   Brew, Bruce J ^c   Spudich, Serena ^d   Bestetti, Arabella ^b   Price, Richard W ^d   Fuchs, Dietmar ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEOPTERIN; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM INFECTION; DISEASE MARKER; DRUG EFFICACY; DRUG TREATMENT FAILURE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREACTIVITY; MACROPHAGE ACTIVATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SYNTHESIS; REVIEW; SYSTEMIC DISEASE; TREATMENT RESPONSE; VIRUS ACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

EID: 77953017654     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-15     Document Type: Review

References (51)

1. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986, 19(6):517-524. 10.1002/ana.410190602, 3729308.
2. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986, 19(6):525-535. 10.1002/ana.410190603, 3014994.
3. Fuchs D, Spira TJ, Hausen A, Reibnegger G, Werner ER, Felmayer GW, Wachter H. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem 1989, 35(8):1746-1749.
4. Fuchs D, Chiodi F, Albert J, Asjo B, Hagberg L, Hausen A, Norkrans G, Reibnegger G, Werner ER, Wachter H. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS (London, England) 1989, 3(5):285-288.
5. Sonnerborg AB, von Stedingk LV, Hansson LO, Strannegard OO. Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS (London, England) 1989, 3(5):277-283.
6. Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, Price RW. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990, 28(4):556-560. 10.1002/ana.410280413, 2252366.
7. Anderson E, Zink W, Xiong H, Gendelman HE. HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr 2002, 31(Suppl 2):S43-54.
8. Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002, 25:537-562. 10.1146/annurev.neuro.25.112701.142822, 12052920.
9. McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, Lanier ER. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997, 42(5):689-698. 10.1002/ana.410420504, 9392567.
10. Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. The Journal of infectious diseases 1997, 175(4):963-966. 10.1086/514001, 9086160.
11. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69(18):1789-1799. 10.1212/01.WNL.0000287431.88658.8b, 17914061.
12. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5(10):e203. 10.1371/journal.pmed.0050203, 2570418,2570418, 18942885.
13. Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis 2005, 40(6):853-858. 10.1086/427877, 15736019.
14. Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 2009, 19(2):169-185. 10.1007/s11065-009-9092-3, 19424802.
15. Gisslen M, Chiodi F, Fuchs D, Norkrans G, Svennerholm B, Wachter H, Hagberg L. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand J Infect Dis 1994, 26(5):523-533. 10.3109/00365549409011810, 7855550.
16. Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. The Journal of infectious diseases 1996, 174(2):294-298.
17. Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999, 21(4):271-276.
18. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS (London, England) 2002, 16(16):2145-2149.
19. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. The Journal of infectious diseases 2007, 196(12):1779-1783. 10.1086/523648, 18190258.
20. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler 1989, 370(9):1063-1069.
21. Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C, Fuchs D. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol 1999, 116(3):435-440. 10.1046/j.1365-2249.1999.00910.x, 1905306, 10361231.
22. Neurauter G, Wirleitner B, Laich A, Schennach H, Weiss G, Fuchs D. Atorvastatin suppresses interferon-gamma -induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol 2003, 131(2):264-267. 10.1046/j.1365-2249.2003.02021.x, 1808628, 12562386.
23. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003, 52(8):313-321. 10.1007/s00011-003-1181-9, 14504669.
24. Nathan CF. Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon gamma. Interferon 1986, 7:125-143.
25. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP, Wachter H. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993, 321(1):89-92. 10.1016/0014-5793(93)80627-7, 8385632.
26. Hoffmann G, Schobersberger W, Frede S, Pelzer L, Fandrey J, Wachter H, Fuchs D, Grote J. Neopterin activates transcription factor nuclear factor-kappa B in vascular smooth muscle cells. FEBS Lett 1996, 391(1-2):181-184. 10.1016/0014-5793(96)00729-6, 8706912.
27. Cirillo P, Pacileo M, S DER, Calabro P, Gargiulo A, Angri V, Granato-Corigliano F, Fiorentino I, Prevete N, R DEP, et al. Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. J Thromb Haemost 2006, 4(10):2248-2255. 10.1111/j.1538-7836.2006.02125.x, 16842491.
28. Hoffmann G, Frede S, Kenn S, Smolny M, Wachter H, Fuchs D, Grote J, Rieder J, Schobersberger W. Neopterin-induced tumor necrosis factor-alpha synthesis in vascular smooth muscle cells in vitro. Int Arch Allergy Immunol 1998, 116(3):240-245. 10.1159/000023950, 9693272.
29. Hoffmann G, Rieder J, Smolny M, Seibel M, Wirleitner B, Fuchs D, Schobersberger W. Neopterin-induced expression of intercellular adhesion molecule-1 (ICAM-1) in type II-like alveolar epithelial cells. Clin Exp Immunol 1999, 118(3):435-440. 10.1046/j.1365-2249.1999.01071.x, 1905438, 10594564.
30. Werner-Felmayer G, Golderer G, Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab 2002, 3(2):159-173. 10.2174/1389200024605073, 12003348.
31. Cano OD, Neurauter G, Fuchs D, Shearer GM, Boasso A. Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells. Neurosci Lett 2008, 438(1):22-5. 10.1016/j.neulet.2008.04.046, 18457922.
32. Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990, 3(9):873-876.
33. Smith DG, Guillemin GJ, Pemberton L, Kerr S, Nath A, Smythe GA, Brew BJ. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol 2001, 7(1):56-60. 10.1080/135502801300069692, 11519483.
34. Werner ER, Bitterlich G, Fuchs D, Hausen A, Reibnegger G, Szabo G, Dierich MP, Wachter H. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci 1987, 41(3):273-280. 10.1016/0024-3205(87)90149-4, 3110526.
35. Freeze ASK, During MJ, Martin JB. Kynurenine metabolites of tryptophan: Implications for neurological diseases. Neurology 1990, 40:691-695.
36. Mayersbach P, Augustin R, Schennach H, Schonitzer D, Werner ER, Wachter H, Reibnegger G. Commercial enzyme-linked immunosorbent assay for neopterin detection in blood donations compared with RIA and HPLC. Clin Chem 1994, 40(2):265-266.
37. Price RW, Brew BJ. The AIDS dementia complex. The Journal of infectious diseases 1988, 158(5):1079-1083.
38. Cinque PKI, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009, 9:625-636. 10.1016/S1473-3099(09)70226-9, 19778765.
39. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47(2):168-173. 10.1097/QAI.0b013e31815ace97, 2628632, 17971711.
40. Letendre S, FitzSimons C, Ellis R, Clifford D, Collier A, Gelman B, McArthur J, Vaida F, Heaton R, Grant I. Correlates of CSF Viral Loads in 1221 Volunteers of the CHARTER Cohort. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, US 2010,
41. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Archives of neurology 2008, 65(1):65-70. 10.1001/archneurol.2007.31, 2763187, 18195140.
42. Hagberg L, Dotevall L, Norkrans G, Larsson M, Wachter H, Fuchs D. Cerebrospinal fluid neopterin concentrations in central nervous system infection. The Journal of infectious diseases 1993, 168(5):1285-1288.
43. Hagberg L, Abdulle S, Gisslén M. Clinical application of cerebrospinal fluid neopterin concentrations in HIV infection. Pteridines 2004, 15:102-106.
44. Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS (London, England) 1999, 13(13):1677-1685.
45. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. The Journal of infectious diseases 2006, 194(12):1686-1696. 10.1086/508750, 17109340.
46. Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 2009, 5(4):e1000395. 10.1371/journal.ppat.1000395, 2668697, 19390619.
47. Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Gunthard HF, Good B, Smith DM, Wolinsky SM, Furtado M, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol 2005, 79(3):1772-1788. 10.1128/JVI.79.3.1772-1788.2005, 544082, 15650202.
48. Caragounis EC, Gisslen M, Lindh M, Nordborg C, Westergren S, Hagberg L, Svennerholm B. Comparison of HIV-1 pol and env sequences of blood, CSF, brain and spleen isolates collected ante-mortem and post-mortem. Acta Neurol Scand 2008, 117(2):108-116.
49. Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. The Journal of infectious diseases 2007, 195(12):1774-1778. 10.1086/518043, 17492593.
50. Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 2009, 4(2):163-174. 10.1007/s11481-008-9143-1, 19067177.
51. Gisslen M, Svennerholm B, Fuchs D, Hagberg L. Neurological efficacy of stavudine, zidovudine, and lamivudine. Lancet 1998, 352(9125):402-403.